Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Dec 7;12(45):7337-40.
doi: 10.3748/wjg.v12.i45.7337.

Safety and efficacy of hepatitis A vaccine in children with chronic liver disease

Hanaa-Mostafa El-Karaksy  1 , Manal-Ismail El-Hawary, Nehal-Mohammad El-Koofy, Rokaya El-Sayed, Mona-Al-Saeed El-Raziky, Samah-Asaad Mansour, Gamal-Mohammad Taha, Fatma El-Mougy
Affiliations

Safety and efficacy of hepatitis A vaccine in children with chronic liver disease

Hanaa-Mostafa El-Karaksy et al. World J Gastroenterol. .

Abstract

Aim: To study the safety and efficacy of hepatitis A vaccine (HAV) in children with chronic liver disease of various etiologies.

Methods: Eleven children with chronic liver disease and thirteen age- and sex-matched controls negative for HAV antibodies were vaccinated against hepatitis A after they gave their informed consent. Children with uncontrolled coagulopathy or signs of hepatic decompensation were excluded. The vaccine (Havrix: 720 ELISA units in 0.5 mL, from GlaxoSmithKline Biologicals) was given intramuscularly in the deltoid in 2 doses 6 mo apart. Children were tested for HAV antibodies one and six months after the 1st dose and one month after the 2nd dose. Total serum bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were determined immediately before and after one month of the 1st dose of the vaccine.

Results: Only 7 out of the 11 patients were positive for HAV antibodies after the 1st dose of the vaccine, as compared to 100% of the controls. One month after the 2nd dose, all patients tested were positive for HAV antibodies. No deterioration in liver functions of patients was noted after vaccination. No adverse events, immediate or late, were reported by the mothers after each dose of the vaccine.

Conclusion: Hepatitis A vaccine is both safe and effective in this small studied group of children with chronic liver disease. Given the high seroconversion rate, post-vaccination testing for HAV antibodies is not needed.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther. 2004;19:715–727. - PubMed
    1. McNeil M, Hoy JF, Richards MJ, Lehmann NI, Dimitrikakis M, Gust ID, Lucas CR. Aetiology of fatal viral hepatitis in Melbourne. A retrospective study. Med J Aust. 1984;141:637–640. - PubMed
    1. Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med. 1998;128:111–114. - PubMed
    1. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases. Am J Gastroenterol. 1995;90:201–205. - PubMed
    1. Hadler SC. Global impact of hepatitis A virus infection changing patterns. In: Hollinger FB, Lemon SM, Margolis H, ed , editors. Viral Hepatitis and Liver Disease. Baltimore: Lippincott Williams & Wilkins; 1990. pp. 14–20.